Bayer AG has reinforced its position as a leader in the radiopharmaceuticals field by inking a deal with the UK's Bicycle Therapeutics, plc that could be worth up to $1.7bn.
The firms are teaming up to develop bicyclic peptides, ie, a peptide arranged around a small-molecule scaffold in two loops,...








